USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Nanoparticle-based Formulation to Drive Transformational Growth Across Inhaled Vaccines and Monoclonal Antibodies
27-Apr-2023
Global
Technology Research
DA9D-01-00-00-00
HC03660-GL-TR_27604
Inhalation drug delivery involves administering drugs to the lungs through the mouth (pulmonary route) or nose (intranasal route), enabling them to bypass the blood-brain barrier. Small molecules have been the main focus for inhalation delivery, but recent R&D and increased interest in inhalable COVID-19 vaccines have led to a shift toward inhalable biologics for conditions where injection delivery is the norm.
This Frost & Sullivan study highlights important formulations for inhalable biologics and examines the factors that drive or limit market growth. The research examines the pipeline of monoclonal antibodies and vaccines in development and evaluates R&D trends, partnership and collaboration trends, funding and investment analysis, patent analysis, and the outlook for inhalable biologics. The study identifies significant growth opportunities for industry players in the field.
Questions this study answers:
1. What factors drive or limit the industry’s growth?
2. What are the innovative methods for formulating inhalable biologics?
3. What does the pipeline analysis for inhalable vaccines and monoclonal antibodies look like?
4. What are the R&D trends and projected developments of the technologies?
5. What are the funding evaluations, patent evaluations, regulatory environments, and trends for partnerships and collaborations for inhalable biologics?
6. What are the growth opportunities for technology developers in the inhalable biologics space?
Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Inhaled Therapeutics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Scope of Analysis
The Need for Inhalation Biologics Formulation
Inhalation Drug Delivery—Introduction
Segmentation—Formulations for Drug Inhalation
Pros and Cons of Formulation and Drug Delivery Systems for Inhalation
Examples of Novel Formulations and Drug Delivery System for Inhalable Biologics
Promising Inhalation Therapy—Advantages of Inhalational Monoclonal Antibodies (mAbs) and Vaccines
Growth Drivers
Growth Restraints
Pipeline Analysis of Inhaled Vaccines and mAbs
Vaccines and mAbs under Clinical Development
Primary Technologies—AttenuBlock Platform Technology (Codon Deoptimization for Live Attenuated Vaccine Candidates)
Primary Technologies—Nanoemulsion Platform (Intranasal Adjuvant Technology)
R&D Trends
Collaboration and Partnership Trends
Funding and Investment Analysis
Patent Analysis
Future Roadmap
Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution
Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution (continued)
Growth Opportunity 2: Partnering with a CDMO that Offers End-to-end Services
Growth Opportunity 2: Partnering with a CDMO that Offers End-to-end Services (continued)
Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration
Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration (continued)
Your Next Steps
Why Frost, Why Now?
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
15 Sep 2026 | Global | Market Research
Vendor Profiles: Advanced Wound Care Management Market, Global, 2025
The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...
11 Sep 2026 | Global | Frost Radar
Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2026
Pharmaceutical commercialization is a multidimensional concept in the successful launch and distribution of a drug. The process includes the development of a pricing strategy that reflects the drug’s value, negotiation with payers to ensure drug cost coverage, regulatory compliance, and the generati...
07 Sep 2026 | Global | Technology Research
Synthetic Antibodies and AI-Optimized Immunotherapies
Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...
28 Aug 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.The issue features advanced medical devices such as active bioelectr...
27 Aug 2026 | Global | Frost Radar
Frost Radar: AI-Powered Molecular Diagnostics, 2026
AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Technology Research |
|---|---|
| Author | Ashish Kaul |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Inhalable Drugs Market |
| Keyword 2 | Inhaled Therapeutics Market |
| Keyword 3 | Lung Disease Therapeutics Market |
| Podcast | No |
| WIP Number | DA9D-01-00-00-00 |